NAD+ precursors in clinical settings
The newly published paper, titled "Emerging strategies, applications and challenges of targeting NAD+ in the clinic," is co-authored by Hilde Loge Nilsen, first author Jianying Zhang, and last author Evandro Fei Fang. The review looks at the potential use of NAD+ precursors in clinical settings.
The research presents key findings from clinical trials, evaluating the safety, absorption, and effectiveness of established NAD+ precursors like nicotinic acid and nicotinamide. Newer compounds such as nicotinamide riboside and nicotinamide mononucleotide are also explored. The study highlights how these compounds may be used in the context of ageing and neurodegenerative diseases.
Additionally, the paper discusses new advancements in production and detection methods. These improvements could greatly enhance research in this area.
Larger studies are needed
While the results are promising, the authors stress the need for larger studies. These studies are necessary to identify optimal dosages, administration methods, and to assess long-term safety. The authors also point out that individuals may respond differently to these compounds. This variability underscores the importance of personalized approaches to aging treatments.
For those interested in exploring this research further, the full paper is available here.